Free Trial
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel
NASDAQ:BCAB

BioAtla Q1 2026 Earnings Results & Report

BioAtla logo
$1.36 +0.06 (+4.62%)
As of 10/16/2026 03:50 PM Eastern

BioAtla beat analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$4.22 versus the -$10.00 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

BioAtla EPS Results

Actual EPS
-$4.22
Consensus EPS
-$10.00
Beat/Miss
Beat by +$5.78
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

BioAtla Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.72 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

BioAtla's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BioAtla's Q1 2026 Quarterly reportQuarterly report
(10-Q)

BioAtla Q1 2026 Earnings FAQ

BioAtla (NASDAQ:BCAB) reported earnings of -$4.22 per share for Q1 2026, beating the consensus estimate of -$10.00. The report was announced on Friday, May 15, 2026.

BioAtla's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for BioAtla on the company's earnings history page.

BioAtla Earnings Headlines

Contrasting BioAtla (NASDAQ:BCAB) and Bicycle Therapeutics (NASDAQ:BCYC)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110357
BioAtla Announces $40 Million Oncology SPV Investment Deal
May 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BCAB/pressreleases/36851340/bioatla-announces-40-million-oncology-spv-investment-deal/
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
October 18 at 1:00 AM  |  Banyan Hill Publishing (Ad)
BioAtla Announces Share Consolidation
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266037/0/en/bioatla-announces-share-consolidation.html
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266019/0/en/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights.html
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value
March 2, 2026  |  quiverquant.comQ
See More BioAtla Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email.

About BioAtla

BioAtla (NASDAQ:BCAB) was a biotechnology company focused on developing antibody-based cancer therapies. The company’s research centered on its Conditionally Active Biologics (CAB) platform, which was designed to create therapeutic antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissue.

BioAtla’s development pipeline included antibody-drug conjugates and other immuno-oncology candidates. Its leading programs included mecbotamab vedotin, also known as BA3011, an antibody-drug conjugate targeting AXL, and ozuriftamab vedotin, or BA3021, an antibody-drug conjugate directed at ROR2. The company evaluated these candidates in clinical studies for solid tumors and other cancers.

Founded in 2007 and headquartered in San Diego, California, BioAtla advanced its programs through clinical development and collaborations intended to support the development of targeted cancer medicines. The company later reduced operations and pursued strategic alternatives after encountering clinical and financial challenges. Public disclosures indicated that BioAtla ultimately wound down its business, so its historical pipeline and platform provide the primary basis for describing the company.

View BioAtla Profile
Earnings Tools